2023
Utility and precision evidence of technology in the treatment of type 1 diabetes: a systematic review
Jacobsen L, Sherr J, Considine E, Chen A, Peeling S, Hulsmans M, Charleer S, Urazbayeva M, Tosur M, Alamarie S, Redondo M, Hood K, Gottlieb P, Gillard P, Wong J, Hirsch I, Pratley R, Laffel L, Mathieu C. Utility and precision evidence of technology in the treatment of type 1 diabetes: a systematic review. Communications Medicine 2023, 3: 132. PMID: 37794113, PMCID: PMC10550996, DOI: 10.1038/s43856-023-00358-x.Peer-Reviewed Original ResearchType 1 diabetesTreatment of peopleSystematic reviewAdvanced hybrid closed-loop systemBaseline glycemic levelsSelf-care burdenOptimization of outcomesContinuous glucose monitoring systemHybrid closed-loop systemAdvanced complicationsStandard careGlucose monitoring systemHypoglycemia riskGlycemic levelsGlycemic variabilityDiabetes therapyDiabetesHealthcare teamInsulin pumpType 1Glucose monitoringInsulin deliveryDevice initiationBehavioral modificationFurther studies
2021
Automated Insulin Delivery
Weinzimer S, Carria L, Van Name M. Automated Insulin Delivery. Contemporary Endocrinology 2021, 75-85. DOI: 10.1007/978-3-030-64133-7_8.ChaptersDiabetes self-management tasksInsulin deliveryHemoglobin A1c levelsT1D Exchange RegistrySelf-management tasksGlycemic targetsA1c levelsDiabetes careContinuous glucose monitoring devicesDiabetes therapyInsulin pumpGlucose monitoring devicesDiabetes technologyRecent dataMost youthMore burdenDiabetes devicesBurdenDeliveryT1DRegistryTherapy
2018
Evaluation of PET Brain Radioligands for Imaging Pancreatic β-Cell Mass: Potential Utility of 11C-(+)-PHNO
Bini J, Naganawa M, Nabulsi N, Huang Y, Ropchan J, Lim K, Najafzadeh S, Herold KC, Cline GW, Carson RE. Evaluation of PET Brain Radioligands for Imaging Pancreatic β-Cell Mass: Potential Utility of 11C-(+)-PHNO. Journal Of Nuclear Medicine 2018, 59: 1249-1254. PMID: 29371405, PMCID: PMC6071501, DOI: 10.2967/jnumed.117.197285.Peer-Reviewed Original ResearchConceptsT1DM subjectsΒ-cell massHealthy controlsΒ-cellsAbdominal organsType 1 diabetes mellitusC-peptide levelsHealthy control subjectsPancreatic β-cell massDeficient insulin secretionReceptor agonist radioligandPET/CTIslets of LangerhansDynamic PET/CTCommon cellular receptorPancreatic bindingDiabetes mellitusDiabetic subjectsControl subjectsNeurologic tissueC-peptideInsulin secretionMean SUVAgonist radioligandDiabetes therapy
2017
The Risk of Severe Hypoglycemia in Type 1 Diabetes Over 30 Years of Follow-up in the DCCT/EDIC Study
Gubitosi-Klug RA, Braffett BH, White NH, Sherwin RS, Service FJ, Lachin JM, Tamborlane WV, Group T. The Risk of Severe Hypoglycemia in Type 1 Diabetes Over 30 Years of Follow-up in the DCCT/EDIC Study. Diabetes Care 2017, 40: dc162723. PMID: 28550194, PMCID: PMC5521975, DOI: 10.2337/dc16-2723.Peer-Reviewed Original ResearchConceptsSevere hypoglycemiaTreatment groupsMean HbADiabetes therapyDCCT/EDIC cohortDCCT/EDIC studyIntensive diabetes therapyIntensive treatment groupSevere hypoglycemia ratesConventional treatment groupDuration of diabetesConventional diabetes therapyType 1 diabetesComplications (DCCT/EDIC) cohortEDIC studySimilar HbAComplications TrialHypoglycemia ratesLower HbADiabetes controlDCCT studyRisk factorsRelative riskHypoglycemiaLower riskAdipocyte Accumulation in the Bone Marrow during Obesity and Aging Impairs Stem Cell-Based Hematopoietic and Bone Regeneration
Ambrosi T, Scialdone A, Graja A, Gohlke S, Jank A, Bocian C, Woelk L, Fan H, Logan D, Schürmann A, Saraiva L, Schulz T. Adipocyte Accumulation in the Bone Marrow during Obesity and Aging Impairs Stem Cell-Based Hematopoietic and Bone Regeneration. Cell Stem Cell 2017, 20: 771-784.e6. PMID: 28330582, PMCID: PMC5459794, DOI: 10.1016/j.stem.2017.02.009.Peer-Reviewed Original ResearchConceptsStem cell-basedHematopoietic regenerationAdipocyte accumulationStem cell-like characteristicsCell-like characteristicsBone resident cellsDipeptidyl peptidase-4Bone marrow cavityCompetitive repopulationLethal irradiationHematopoietic nicheBone marrowCell-basedPeptidase-4Osteogenic lineageAged animalsBone healingDiabetes therapyAdipocyte lineageBoneMarrow cavityAge-dependentMolecular identityObesityAdipogenic lineages
2015
Changing trends in type 2 diabetes mellitus treatment intensification, 2002-2010.
McCoy RG, Zhang Y, Herrin J, Denton BT, Mason JE, Montori VM, Smith SA, Shah ND. Changing trends in type 2 diabetes mellitus treatment intensification, 2002-2010. The American Journal Of Managed Care 2015, 21: e288-96. PMID: 26167776.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAdolescentAdultAge FactorsAgedBlood GlucoseComorbidityDiabetes Mellitus, Type 2Drug Therapy, CombinationFemaleGlycated HemoglobinHumansHypoglycemic AgentsIncretinsInsurance Claim ReviewMaleMetforminMiddle AgedResidence CharacteristicsRetrospective StudiesSex FactorsSocioeconomic FactorsSulfonylurea CompoundsUnited StatesYoung AdultConceptsTreatment intensificationCox proportional hazards regression analysisNational administrative data setProportional hazards regression analysisRetrospective secondary data analysisDiabetes treatment intensificationOptimal diabetes careHazards regression analysisDiabetes-related complicationsAdults 18 yearsTreatment-naïve adultsNon-Hispanic whitesComorbidity burdenMetformin monotherapySulfonylurea useMetformin prescriptionThiazolidinedione useGlycemic controlKaplan-MeierMean ageDiabetes careSignificant confoundersSecondary data analysisAdministrative data setsDiabetes therapy
2012
Type 1 diabetes therapy beyond T cell targeting: monocytes, B cells, and innate lymphocytes.
Wong F, Wen L. Type 1 diabetes therapy beyond T cell targeting: monocytes, B cells, and innate lymphocytes. The Review Of Diabetic Studies 2012, 9: 289-304. PMID: 23804267, PMCID: PMC3740697, DOI: 10.1900/rds.2012.9.289.Peer-Reviewed Original ResearchConceptsInnate lymphocytesB cellsT cell targetingNatural killer cellsRecent clinical trialsPathogenesis of T1DType 1 diabetesType 1 diabetes therapyKiller cellsSpecific therapyClinical trialsT cellsDisease processDiabetes therapyMultifactorial diseaseCell pathwaysMultiple cell typesDiabetesT1DLymphocytesTherapyMonocytesDiseaseSuitable targetCell types
2002
Type 2 diabetes therapy
Mayerson AB, Inzucchi SE. Type 2 diabetes therapy. Postgraduate Medicine 2002, 111: 83-95. PMID: 11912999, DOI: 10.3810/pgm.2002.03.1140.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply